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Abstract
Among the US civilian noninstitutionalized population aged 14 to 59 years in 2013 to 2016, 
prevalence of Trichomonas vaginalis infection in urine was 1.3% overall. Prevalence was 2.1% 
among females, 0.5% among males, and highest at 9.6% among non-Hispanic black females. 
Estimate instability limited analysis of factors beyond sex, age, and race/Hispanic ethnicity.
Trichomonas vaginalis is a treatable sexually transmitted parasitic infection associated with 
preterm delivery among women.1,2 In 2001 to 2004, estimated prevalence among US 
civilian, noninstitutionalized females aged 14 to 49 years was 3.1%, based on polymerase 
chain reaction results from vaginal swab specimens collected for the National Health and 
Nutrition Examination Survey (NHANES).3 We assessed T. vaginalis prevalence among US 
civilian, noninstitutionalized males and females aged 14 to 59 years from 2013 to 2016 by 
demographic, health, and sexual behavior factors using nucleic acid amplification test results 
from NHANES urine specimens. This is the first publication of 2013 to 2016 T. vaginalis 
infection estimates which includes adolescents aged 14 to 17 years.4,5 We also examined the 
stability of these estimates, as well as nonresponse, which can bias estimates.
MATERIALS AND METHODS
The NHANES is a complex, multistage probability sample survey of the US civilian, 
noninstitutionalized population6 administered continuously since 1999; data are released as 
combined 2-year cycles (e.g., 2013–2014). Demographic data are collected during a home 
interview. Biospecimens, and reproductive health and sexual behavior data, are subsequently 
collected in a mobile examination center. The NHANES is approved by the National Center 
for Health Statistics ethics review board; because only secondary, deidentified data were 
used, further institutional review board approval was not required.
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T. vaginalis infection was assessed using urine specimens from male and female participants 
aged 14 to 59 years with the Gen-Probe Aptima T. vaginalis assay (Hologic; Gen-Probe, San 
Diego CA).7 Assay performance was verified using male and female urine specimens 
previously found to be positive or negative for T. vaginalis nucleic acid; proficiency panels 
provided by the College of American Pathologists were tested 3 times per year to ensure 
ongoing assay accuracy. T. vaginalis infection results and sexual behavior data for 14- to 17-
year-olds were accessed from a National Center for Health Statistics Research Data Center8; 
data for other participants are publicly available.9
Because of the low prevalence of T. vaginalis infection, to increase stability of estimates, 
data from 2013 to 2014 and 2015 to 2016 were concatenated. Cumulative response rates 
(i.e., home interview participation rate, sexual behavior questionnaire participation rate, and 
T. vaginalis test completion rate among sampled participants) were assessed using age 
group–specific sample screening, interview, and examination participant counts.10 Response 
rate calculations were limited to participants aged 20 to 59 years because participant counts 
were not provided for the 14- to 19-year age group. Response rates were adjusted to account 
for the 2015 to 2016 sample screening rate of 94.3%.10
Nationally representative, weighted estimates of T. vaginalis prevalence and 95% confidence 
intervals (CIs) were calculated for the total population, by sex, and by demographic, health, 
and sexual behavior characteristics separately among males and females. Estimates with 
relative standard errors (RSEs) ≥30% and <50% may be unstable and should be interpreted 
with caution; estimates with RSE ≥50% were not shown because these are unstable. 
Analyses were performed using SAS software version 9.411 and SAS-callable SUDAAN 
version 11.0.1.12
RESULTS
The 2013 to 2016 interview response rate among participants aged 20 to 59 years was 
61.9%. T. vaginalis test completion was 58.4%. Sexual behavior questionnaire participation 
was 52.3%.
T. vaginalis prevalence among males and females aged 14 to 59 years was 1.3% (95% CI, 
1.0%–1.7%; Table 1). Prevalence was2.1% (95% CI, 1.6%–2.8%) among females and 
significantly lower among males (0.5%; 95% CI, 0.3%–0.7%).
T. vaginalis prevalence was very low (0.7%; 95% CI,0.4%–1.5%) among females aged 14 to 
19 years (Table 1). Prevalence was 2.7% (95% CI, 1.8%–4.0%) among women aged 20 to 29 
years and did not differ significantly for women aged 30 to 39 or 40 to 49 years, but was 
lower (1.4%; 95% CI, 0.8%–2.5%) among women aged 50 to 59 years. Among males aged 
14 to 19 and 30 to 39 years, estimates were unstable; no significant differences in prevalence 
were identified between males in other age groups, although these estimates were potentially 
unstable.
Compared with non-Hispanic white females (0.8%; 95% CI, 0.4%–1.5%), T. vaginalis 
prevalence was significantly higher among non-Hispanic black females (9.6%; 95% CI, 
7.3%–12.5%) but not Hispanic females (1.4%; 95% CI, 0.8%–2.2%; Table 1). Prevalence 
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among non-Hispanic black males was 3.4% (95% CI, 2.3%–4.9%); estimates among males 
were unstable for all other race/ethnicity groups.
Among females, increasing poverty level, lower educational attainment, unmarried status, 
and having been born in the United States were significantly associated with T. vaginalis 
infection (Table 1). Similar findings were observed among males. However, most of these 
estimates were potentially unstable; those with RSEs ≥50% are not shown.
Among females, younger age at sexual debut, greater number of lifetime and/or past 12 
months sex partners, and chlamydia infection in the past 12 months were significantly 
associated withT. vaginalis infection (Table 2). Among males, most of these estimates were 
unstable and not shown.
DISCUSSION
This is the first report of T. vaginalis infection prevalence in 2013 to 2016 that includes data 
from adolescents aged 14 to 17 years. Overall prevalence among those aged 14 to 59 years 
was almost 4-fold higher among females than males, and almost 11-fold higher among non-
Hispanic black females than non-Hispanic white females. Prevalence was higher among 
people with lower family income, less education, and who were unmarried. Younger age at 
sexual debut and higher number of sex partners were associated with higher T. vaginalis 
prevalence among females.
These findings cannot be directly compared with 2001–2004 NHANES results. Although 
one study has shown identical detection of T. vaginalis from urine and vaginal swabs,13 
others found detection in urine is lower.14,15 In 2001 to 2004, polymerase chain reaction 
testing was conducted, which is less sensitive than the nucleic acid amplification test used in 
2013 to 2016.14 Despite these differences, the current findings highlight similar disparities in 
burden of T. vaginalis infection by race/ethnicity and offer novel information on prevalence 
among adolescents.
Females aged 14 to 19 years seemed to have less T. vaginalis infection than those aged 20 to 
29 years; estimated prevalence among males aged 14–19 years was unstable and not 
reported. Estimates among males were also unstable when stratified by race/ethnicity and by 
most sexual and health factors, despite combining data from two 2-year cycles. A previous 
publication focusing on men aged 18 to 59 years did not address the instability of many 
reported estimates.4 Additional years of data might lend stability to these estimates. 
However, the low prevalence observed among males may be due to the use of urine 
specimens; penile meatal swabs have been shown to be more sensitive for detecting T. 
vaginalis.16,17 Test sensitivity also is lower in urine specimens from males (74%) compared 
with females (88%).14
In addition, a number of estimates presented have RSEs between 30% and 50% and should 
be interpreted with caution, as these may be unstable. Crude and model-adjusted T. vaginalis 
prevalence among males and females aged 18 to 59 years were recently published using a 
single cycle (2013–2014) of NHANES data.5 However, even when data are combined across 
multiple cycles, as in our analysis, stratification by additional factors within sex increases 
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the likelihood of unstable estimates for uncommon outcomes such as T. vaginalis infection. 
Therefore, effect measure modification (i.e., interaction) may be difficult to evaluate and 
account for, if necessary, in statistical models. In the stratified analyses we conducted among 
females to explore relationships between race/ethnicity, age group, family income, and 
educational attainment, most estimates were unstable.
Decreasing NHANES cumulative response is an additional concern. Only examination 
participants were asked to provide specimens for T. vaginalis testing and complete the sexual 
behavior questionnaire. In addition, any examination participant may decline to provide a 
urine specimen, or to complete the sexual behavior questionnaire. Cumulative examination 
response among people sampled for NHANES has decreased to 59% in 2015 to 20168; 
among adults aged 20 to 59 years in 2013 to 2016, cumulative response to the sexual 
behavior questionnaire was only 52%. These low cumulative response rates further 
contribute to the lack of statistical power and potential instability of estimates, and may also 
produce biased T. vaginalis prevalence estimates. Postsurvey weighting adjustments to 
account for nonresponse across demographic subgroups and poststratification of survey 
weights to known population totals, both of which are used for NHANES,18 may reduce 
nonresponse bias, but only if responders and nonresponders have similar response 
propensities and respond similarly with respect to the survey measures of interest.19 These 
assumptions may be invalid, particularly for sensitive information such as sexual behavior. 
Although nonresponse may not necessarily result in biased survey estimates, efforts to 
decrease nonresponse, such as monetary incentives, which are used for NHANES,20 may 
increase bias for some estimates.19 A recent publication examining trends in chlamydia 
prevalence among young women using data from the National Surveys of Attitudes and 
Sexual Lifestyles has noted similar concerns.21
In conclusion, this analysis provides national estimates of T. vaginalis infection prevalence 
in urine specimens from the 2013–2016 US civilian, noninstitutionalized population aged 14 
to 59 years and is the first report to include data from adolescent boys and girls during this 
period. Low infection prevalence among most subpopulation groups constrains detailed 
exploration of factors associated with this infection using NHANES data. Other data sources 
are needed to understand the disproportionate burden of T. vaginalis infection, particularly 
among non-Hispanic blacks.
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